High expression of MERTK was also significantly associated with BRAFV600E mutations (12% of the CRC65 cell line panel and 13% of the QUASAR 2 cohort carry the mutation, Fig EV5D) and stage T4 tumours, while low cytoplasmic/membranous expression was associated with wild‐type BRAF and stage T2/T3 tumours (two‐sided Fisher's exact test P < 0.05, Table EV2D). The gene discussed is MERTK; the disease is neoplasm.